The risk of invasive fungal disease in CLL patients treated with ibrutinib may be higher than previously thought, a new study suggests. Unusual presentations of IFD were seen in 35 patients with CLL and non-Hodgkin lymphoma, Israeli clinicians report in the journal Mycoses. The cases were characterised by early-onset aspergillus infections in non-neutropenic patients who ...
Ibrutinib-associated invasive fungal disease seen in patients with CLL
By Michael Woodhead
17 Sep 2019